Company intelligence / Profile preview
Zhitong Biopharma
Shanghai, Shanghai, Chinazhitongbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Zhitong Biopharma is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative antibody-based therapeutics for oncology. The company leverages its proprietary Zhi-Body platform to engineer multi-specific antibodies and next-generation antibody-drug conjugates (ADCs) designed to overcome resistance in solid tumors. Its lead programs focus on high-value targets such as Claudin 18.2 and immune checkpoints like PD-1 and TIGIT. Zhitong Biopharma aims to provide more effective treatment options for patients with gastrointestinal and lung cancers through precision biologics.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Zhitong Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhitong Biopharma.